T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of such therapies. T-Cypher’s integrated platform, D-Cypher, overcomes these challenges.
Biotechnology, D-Cypher, Autoimmune
No funding announced yet
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as T-Cypher Bio? We’re happy to assist you with our Startup Sourcing service.